HLA-A*0201 & B2M & HBV (FLLTRILTI)

HLA-A*0201 & B2M & HBV (FLLTRILTI) 製品リスト

  • 属性

    Protein (2)

  • 製品ライブラリ

    オンライン (2)

  • Human (2)

  • タグ

    His Tag & Avi Tag (2)

  • マーカー

    Biotin-labeled (1)PE Labeled (1)

製品番号発現システム製品説明タンパク質の構造純度特性
HLT-H82E9
Human
HEK293
Biotinylated Human HLA-A*02:01&B2M&HBV (FLLTRILTI) Complex Protein (Monomer, MALS verified)
HLV-HP2E4
Human
HEK293
PE-Labeled Human HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein
総数量2
  • 1

HLA-A*0201 & B2M & HBV (FLLTRILTI)バックグランド

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). The hepatitis B virus attacks the liver and can cause both acute and chronic diseases that put people at high risk of death from cirrhosis and liver cancer. The virus is most commonly transmitted from mother to child during birth and delivery, as well as through contact with blood or other body fluids. Hepatitis B virus (HBV) is a member of the hepadnaviral family. The virus particle (virion) consists of an outer lipid envelope and an icosahedral nucleocapsid core composed of the core protein. The nucleocapsid encloses the viral DNA and a DNA polymerase that has reverse transcriptase activity. The outer envelope contains embedded proteins that are involved in viral binding of, and entry into, susceptible cells. The surface antigens (HBsAg) decorating the lipid envelope of HBV are produced in excess during the life cycle of the virus, and its presence in blood indicates current hepatitis B infection. The Human HLA-A*0201 HBV ( FLLTRILTI) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and FLLTRILTI peptide of the HBV.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
GRN Gene Therapy(Eli Lilly And Company)PR-006Phase 2 ClinicalEli Lilly And CompanyFrontotemporal Dementia
詳細
TAK-594DNL-593; PTV:PGRN; TAK-594Phase 2 ClinicalDenali Therapeutics IncFrontotemporal Dementia
詳細
AVB-101AVB-101Phase 2 ClinicalAviadoBio LtdFrontotemporal Dementia
詳細
AL-101GSK-4527226; AL-101Phase 2 ClinicalAlector IncNerve Degeneration; Alzheimer Disease; Parkinson Disease; Frontotemporal Dementia; Amyotrophic Lateral Sclerosis
詳細
PBFT-02PBFT-02Phase 2 ClinicalPassage Bio IncFrontotemporal Dementia
詳細
AG-01(A&G Pharm)AG-01(A&G Pharm)Phase 1 ClinicalA&G PharmaceuticalTriple Negative Breast Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung
詳細
  • 製品リスト
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8